IGM Biosciences Stock: Bad News With No Turnaround In Sight
IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...
Crude Oil Surges 3%; Delta Air Lines Posts Better-Than-Expected Earnings
Delta Air Lines, Inc. DAL reported better-than-expected fourth-quarter results and issued 2025 guidance. Delta reported ...
Nasdaq Down Over 2%; Walgreens Posts Upbeat Results
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 400 points on Friday. The Dow traded ...
IGM Biosciences (IGMS) was downgraded to a Sell Rating at Morgan Stanley
IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The ...
IGM Biosciences cuts workforce, halts a couple of product developments
IGM Biosciences (NASDAQ:IGMS) announced that it is currently evaluating internal options as well as potential strategic alternatives. Under these changes, it will halt further development of imvotamab ...
IGM to slash 73% of workforce, halt two drug programs
IGM Biosciences (NASDAQ:IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug ...
Balanced Perspective on IGM Financial: Hold Rating Amid Valuation Concerns and Competitive Pressures
Analyst Tom Mackinnon of BMO Capital maintained a Hold rating on IGM Financial (IGIFF – Research Report), retaining the price target of ...
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Average Rating of “Moderate Buy” from Analysts
Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat ...